Key Points
- A research team at UNIST revealed that the oxygen-sensing protein PHD3 enters mitochondria to inhibit cancer cell proliferation in clear cell renal cell carcinoma.
- The findings are notable because they uncover a novel chemical mechanism where PHD3 directly curbs the metabolic enzyme PC, offering new potential targets for kidney cancer therapies.
- Supported by the National Research Foundation of Korea, the breakthrough highlights South Korea's growing academic and biomedical research contributions on the global stage.
Summary South Korean researchers have uncovered a crucial cellular mechanism that could pave the way for innovative therapies against kidney cancer. A research team led by Professor Yoon Hye-jin at the Ulsan National Institute of Science and Technology (UNIST) demonstrated how a specific oxygen-sensing protein acts as a molecular brake on tumor growth inside kidney cancer cells.
Clear cell renal cell carcinoma (ccRCC) accounts for roughly 70 percent of all kidney cancer cases and is notorious for its ability to adapt and thrive in hypoxic (low-oxygen) conditions. As solid tumors expand rapidly, their blood supply often struggles to keep up, creating an oxygen-deprived environment. Normally, such stress would slow down cell growth, but ccRCC cells alter their metabolism to survive and proliferate aggressively.
The UNIST team discovered that an oxygen-sensing protein known as PHD3 plays a decisive role inside the mitochondria—the powerhouse of the cell. According to the study, PHD3 enters the mitochondria and binds directly to pyruvate carboxylase (PC), a vital metabolic enzyme that replenishes nutrients consumed during cellular growth. Rather than destroying the enzyme or decreasing its quantity, PHD3 chemically modifies PC by attaching a hydroxyl group (an oxygen and hydrogen bond), effectively halting its metabolic activity and putting the brakes on cancer progression.
However, under severe hypoxia, the amount of PHD3 entering the mitochondria drops sharply. This leaves the PC enzyme uninhibited, causing cancer metabolism, mitochondrial respiration, cell proliferation, and tumor cell migration to surge. In laboratory tests where researchers intentionally reduced PHD3 levels, kidney cancer cells exhibited marked increases in growth and mobility.
Historically, PHD3 was primarily thought to function within the main body of the cell (the cytoplasm). This study marks a milestone by revealing its direct regulatory action inside the mitochondria, opening promising new avenues for targeted kidney cancer treatments. Supported by the National Research Foundation of Korea and UNIST, the findings were published in the international scientific journal Experimental & Molecular Medicine.
Sponsored · Ad